Choosing a route is more than choosing between a needle and a spray. It changes where care happens, who administers the product, what equipment is needed, and which research is relevant. Convenience can help a plan fit daily life, but it does not establish clinical superiority.
This comparison covers prescribed NAD+ injections, clinician-administered IV infusions, and compounded nasal preparations. Oral NR and NMN are different compounds and belong in a separate evidence discussion. Do not convert an amount or schedule from one route to another yourself.
There is no universal route winner. Compare the relevant evidence and the practical responsibilities of each proposed plan.
IV infusion: ask about the whole appointment
An IV service involves a clinical encounter, access to a vein, and observation appropriate to the treatment. Ask who evaluates you, who administers the infusion, and what happens if symptoms occur. Confirm the expected visit length without assuming that the infusion itself is the only time involved.
When comparing clinics, include travel, waiting, parking, and the possibility of repeated visits. A package discount can create a commitment before you know whether continuing makes sense. Our local-provider guide includes practical questions for a first call.
Home injection: convenience brings handling responsibilities
A home prescription may reduce travel, but you need clear instructions for the actual product and device. Ask how training is provided, how to reach the prescribing team, and which pharmacist can clarify the label. Concentration, syringe markings, storage, and the allowed use period must agree.
Do not use an online dosing chart as a substitute for that instruction. A refill can have different details. The prescription-label guide helps you identify what needs clarification before use.
Nasal spray: a different formulation and device
A nasal preparation avoids an injection, which may matter to someone uncomfortable with needles. It still needs a product-specific assessment. Ask about the formulation, device, cleaning, storage, and the directions for that particular prescription.
Do not assume an IV or injection study proves the nasal preparation delivers the same clinical results. The CoreAge Rx review covers its advertised nasal and injectable options while keeping those routes distinct. The clinician should explain the rationale for the one being proposed to you.
Compare the evidence by route
The 2019 NAD+ metabolism pilot used an IV infusion. The 2026 retrospective tolerability paper also concerns IV administration. Those sources can inform a discussion of their own settings, but they are not head-to-head proof that home injections or nasal sprays produce equivalent benefits.
If a provider says one route is more potent, ask what the comparison means: concentration, measured exposure, a laboratory marker, or an outcome patients can feel. Those are not interchangeable. Our evidence guide offers a way to read the claim more precisely.
Compare care and cost together
Ask for the total for the proposed plan, the follow-up arrangements, and a clear stopping or reassessment point. A clinic visit may include services a medication shipment does not; a home plan may include support a headline infusion price excludes.
Use the cost guide to compare actual quotes. If you are uncertain which setting fits, begin with your existing clinician and describe your concern before selecting a product. The most convenient route is only useful if the overall care plan is appropriate.
Explore each route in more detail.
Read the dedicated guides to IV therapy, at-home injections, nasal spray, oral supplements, and patches. Liposomal and sublingual products need formulation-specific evidence. Eye drops, suppositories, and dermal products should not borrow evidence from another route.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Grant et al. (2019): NAD+ infusion metabolome pilot Small human IV study; metabolic observations do not prove longevity or everyday benefits.
- Reyna et al. (2026): retrospective IV tolerability pilot Route-specific retrospective tolerability evidence; not proof of effectiveness for home injections.
- CoreAge Rx: NAD+ Injectable product page Provider advertising; product page displays a different starting price of $93/month.
- CoreAge Rx: NAD+ Nasal Provider description of a different administration route.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.